文献速递创面修复显微修复重建

感染左心室辅助装置皮瓣覆盖影响患者结局

Flap Coverage of Infected Ventricular Assist Devices Influences Patient Outcomes.
PubMed 文献 · Ann Plast Surg · 2022-12-21

回顾性分析2012至2022年罗切斯特大学医学中心568例左心室辅助装置(LVAD)感染再入院患者,其中117例清创后分别行一期闭合(34例)、二期愈合(31例)或皮瓣覆盖(52例)。皮瓣覆盖组终生因感染重返手术室率低于一期闭合组(P=0.01、0.02),90天并发症无差异。

要点

  • 感染LVAD清创后,皮瓣或负压创面治疗二期愈合较一期闭合降低终生因感染重返手术室率。
  • 皮瓣覆盖与一期闭合相比,90天并发症发生率无显著差异(P=0.76、P=0.58)。
  • 确定性覆盖时培养阳性与阴性相比,并发症和重返手术室率均无显著差异(P=0.79、P=0.40)。

核心结论

  • 感染LVAD用局部皮瓣覆盖或通过负压创面治疗让其肉芽生长,可降低患者终生因未来感染重返手术室率,且不增加90天并发症。
  • 若伤口有健康肉芽组织,培养阳性不应影响重返手术室的时机。

研究设计与样本

  • 回顾性研究,通过医院病历档案识别2012至2022年罗切斯特大学医学中心置入心室辅助装置后因LVAD感染再入院的患者,平均回顾随访3.2年。
  • 568例LVAD相关感染住院患者中117例接受手术清创,其中34例行一期闭合、31例行二期愈合(负压创面治疗联合刃厚皮片移植)、52例行皮瓣覆盖(胸大肌、大网膜、背阔肌或垂直腹直肌肌皮瓣)。
  • 采用χ²检验进行结局比较分析。

主要发现

  • 终生因感染重返手术室发生率:一期闭合组高于二期愈合组(P=0.01)和皮瓣重建组(P=0.02)。
  • 90天并发症发生率:一期闭合组与二期愈合组比较P=0.76,与皮瓣重建组比较P=0.58,均无显著差异。
  • 确定性覆盖时培养阳性83例中24例发生术后并发症、15例需终生因感染重返手术室,培养阴性34例中9例发生并发症、4例需重返手术室,并发症与重返手术室比较P=0.79、P=0.40,均无显著差异。
  • 培养数据进一步分为细菌培养73例与真菌培养10例,两组并发症与重返手术室比较P=0.40、P=0.39,均无显著差异。

临床怎么用

  • 作者结论认为,感染LVAD采用局部皮瓣覆盖或负压创面治疗允许肉芽生长,可降低终生因未来感染重返手术室率且不增加90天并发症。
  • 作者结论认为,只要伤口存在健康肉芽组织,培养阳性不应影响重返手术室的时机。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of left ventricular assist devices (LVADs) for patients with end-stage cardiac failure awaiting heart transplantation has become increasingly common. However, ventricular assist device-related infections remain a major problem complicating their long-term use. Poor data exist to determine how to manage these infections after operative debridement. METHODS: Patients who underwent insertion of a ventricular assist device and had a subsequent readmission for LVAD infection at the University of Rochester Medical Center from 2012 to 2022 were identified through accessing the medical records archives of the hospital. Patients were followed retrospectively for an average of 3.2 years. Patient demographics, preoperative diagnosis/disease state, type of ventricular assist device inserted, postoperative day of ventricular assist device infection onset, infectious organism identified at initial washout, infectious organism identified at time of definitive device coverage, timing of coverage procedure after the initial washout for infection, type of flap used for coverage, 90-day complications after definitive coverage, and lifetime return to operating room for infection were reviewed. Comparison analysis with a χ 2 test was used to analyze outcomes. RESULTS: Of 568 patients admitted with an LVAD-related infection 117 underwent operative debridement. Of these, 34 underwent primary closure, 31 underwent closure with secondary intention (negative pressure wound therapy with split thickness skin grafting), and 52 were closed with a flap (pectoralis, omental, latissimus, or vertical rectus abdominus musculocutaneous flap). There was a statistically significant higher incidence of return to the operating room (RTOR) for infection over a lifetime with primary closure compared with secondary intention and flap reconstruction ( P = 0.01, 0.02), but no difference in 90-day complications ( P = 0.76, P = 0.58). Eighty-three patients had a positive culture upon definitive coverage with 24 having a postsurgical complication, 15 of which required lifetime RTOR for infection. Thirty four were closed with negative cultures with 9 having a complication and 4 requiring RTOR for infection. This was not statistically significant for complications or RTOR ( P = 0.79, 0.40). Culture data were further substratified into bacterial cultures (n = 73) versus fungal cultures (n = 10), and there was no statistically significant difference between these compared with complications or RTOR ( P = 0.40, 0.39). CONCLUSIONS: Coverage of infected LVADs with locoregional flaps or allowing to granulate using wound vac therapy has a decreased lifetime RTOR for future infections for these patients without increase in 90-day complications. Timing of RTOR should not be impacted by positive cultures provided there is healthy granulation tissue in the wound.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Sweitzer K, Butterfield J, Hubert J, et al. Flap Coverage of Infected Ventricular Assist Devices Influences Patient Outcomes. Ann Plast Surg. 2022. PMID: 36729072. doi:10.1097/SAP.0000000000003408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。